1. Scrip

Third Death In Audentes’ XLMTM Gene Therapy Trial

But Companies Remain 'Committed'

 
• By Ian Haydock

Astellas subsidiary says it “remains committed” to on-hold program in high-need disease despite fatal events.

Gene therapy in bottle and syringe for injection. Gene therapy or gene transfer used for treatment or prevention disease as cancer, cystic fibrosis. Medical genetic and research technology concept.
Third Death In XLMTM Trial • Source: Shutterstock

A third patient participating in Audentes Therapeutics, Inc.’s Phase I/II ASPIRO clinical trial evaluating the gene therapy resamirigene bilparvovec (AT132) in patients with X-linked myotubular myopathy (XLMTM) has died, taking to three the number of deaths in the study.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D